Getting “stuck” on a thought, action, or conversation can be a symptom of HD—not stubbornness. New research suggests perseveration may begin earlier than previously thought and highlights the value of caregiver perspectives.

uniQure reports that after 4 years, people given high-dose AMT-130 continue to show signs of slower HD progression, providing hope for their recent regulatory submission. But the new analyses are nuanced. We unpack the hopeful, but complex results.

September brought progress across the HD research landscape. From brain waves and visual thinking to DNA repeats, nutrition, inclusive care, new technologies, and encouraging SKY-0515 data, we round up a busy month in Huntington’s disease research.